肝癌细胞免疫治疗进展  

Cellular immunotherapy of hepatocellar carcinoma

作　　者：杨帆[1,2] 张琪[1,2] 陈规划 

机构地区：[1]中山大学附属第三医院岭南医院生物治疗中心,广州510630 [2]肝脏疾病生物治疗临床转化广东普通高校重点实验室,广州510630 [3]中山大学附属第三医院肝脏外科,广州510630

出　　处：《外科研究与新技术》2013年第4期262-266,共5页Surgical Research and New Technique

基　　金：国家十二五科技重大专项课题资助项目(2012ZX10002016-023);国家自然科学基金资助项目(81372243)

摘　　要：肝癌的治疗目前采用手术为主的综合治疗,但是由于原发性肝癌起病隐匿,多数患者在临床诊断时已失去了手术治疗的机会,即使是手术切除后也容易复发,缺乏有效的治疗药物和手段,总的治疗效果并不理想。生物治疗作为继手术、放疗、化疗后肿瘤治疗的第四种模式,已显示了良好的应用前景。At present,surgery-based comprehensive therapy plays a dominant role in the treatment of hepatocellular carcinma( HCC). However,the majority of patients had no opportunity to undergo surgical treatment when diagnosis was confirmed. Furthermore,there is a high risk of tumor recurrence for patients with HCC even after surgical resection. The overall curative effect of HCC is far from satisfaction. Cancer biotherapy has now truly matured into the fourth modality of cancer treatmnet and proved to be useful in conjunction with surgery,chemotherapy and radiotherapy. The purpose of this article is to review the current status and progress of cellular immunotherapy for HCC

关 键 词：肝癌 细胞免疫治疗 进展 

分 类 号：R735.7[医药卫生—肿瘤]